联系方式电子邮箱：wangjj87@mail.sysu.edu.cn
办公地址：中国广州大学城外环东路132号中山大学药学院429室，邮编：510006
?简单介绍王军舰 博士，中山大学药学院教授、博士生导师，广东省成药性评估及评价工程实验室副主任，广东省****基金获得者，中山大学“****二期”青年杰出人才。主要从事肿瘤药理学和抗肿瘤创新药物研究工作，致力于发现和确证具有肿瘤治疗价值的药物作用新靶点，研发抗肿瘤创新药物，探索肿瘤耐药性作用机制，为癌症治疗提供新策略。在 Nature Medicine, Nature Communications 等国际专业权威期刊发表研究性论文40余篇。申请专利6项，其中PCT专利3项。获得2016年国际前列腺癌基金会Challenge Award。兼任 Cell Biology International 杂志副主编（Associate Editor）、《药学学报》及 Acta Pharmaceutica Sinica B 青年编委、广东省药理学会药物筛选与评价专业委员会副主任委员、广东省药理学会抗炎免疫专业委员会副主任委员、中国药理学会表观遗传药理专业委员会委员。
?
招生招聘信息
课题组长期招聘具有药理学、肿瘤学、化学生物学或分子细胞生物学背景，对肿瘤药理学和抗肿瘤创新药物研发感兴趣的博士后和专职研究员，课题组将提供额外每年5-10万津贴。
欢迎对肿瘤药理学和抗肿瘤创新药物研发感兴趣的考生，积极联系报考本课题组硕士和博士研究生。?
?研究方向1）具有肿瘤治疗价值的新靶点（核受体及表观遗传因子）的发现和确认；
2）抗肿瘤创新药物研发；
3）肿瘤耐药与肿瘤免疫治疗。
?教育经历2006年9月至2009年6月 博士 中国科学院广州生物医药与健康研究院
2007年8月至2007年10月 MERIT Student 香港中文大学
2002年9月至2005年6月 硕士 中山大学
1998年9月至2002年6月 学士 内蒙古大学
?工作经历2017年9月 至今 教授 中山大学药学院
2014年9月 至 2017年8月 助理科学家 美国加利福尼亚大学戴维斯分校
2010年5月 至 2014年8月 博士后 美国加利福尼亚大学戴维斯分校
2009年7月 至 2009年12月 助理研究员 中国科学院广州生物医药与健康研究院
2005年7月 至 2006年8月 研究助理 中国科学院广州生物医药与健康研究院
?社会/学术任职Cell Biology International（Wiley），副主编?????
Acta Pharmaceutica Sinica B及《药学学报》，青年编委?
美国癌症协会（AACR），会员???
国家自然科学基金函评专家?
中国药理学会表观遗传药理专业委员会，委员
中国药理学会抗炎免疫药理专业委员会，委员
广东省药理学会药物筛选与评价专业委员会，副主任委员
广东省药理学会抗炎免疫药理专业委员会，副主任委员
广东省药理学会肿瘤药理专业委员会，常务委员
广东省精准医学应用学会自身免疫病分会，常务委员
?
科研项目1. 国家自然科学基金面上项目，2019.01-2022.12，项目负责人?
2. 广东省****基金项目，2019.10-2023.09，项目负责人
3. 广州市民生科技攻关项目，2020.03-2023.02，合作方负责人
4. 中山大学青年教师重点培育项目，2019.01-2020.12，项目负责人
5. 广东省手性分子与药物发现重点实验室开放课题，2019.07-2021.07，项目负责人
6. 中山大学“****二期”启动项目，2017.09-2022.08，项目负责人
?
论著专利代表性论文
Junjian Wang, June X. Zou, Xiaoqian Xue, Demin Cai1, Yan Zhang, Zhijian Duan, Qiuping Xiang, Joy C. Yang, Maggie C. Louie, Alexander D. Borowsky, Allen C. Gao, Christopher P. Evans, Kit S. Lam, Jianzhen Xu, Hsing-Jien Kung, Ronald M. Evans, Yong Xu, and Hong-Wu Chen. 2016 ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nature Medicine. 22(5):488-96 doi:10.1038/nm.4070. (This paper is highlighted in?NATURE, 532, 9, 2016 and NATURE REVIEWS UROLOGY, 13, 237, 2016)
Junjian Wang, Haibin Wang, Lingyu Wang, Demin Cai, Zhijian Duan, Yanhong Zhang, Peng Chen, June X. Zou, Jianzhen Xu, Xinbin Chen, Hsing-Jien Kung, Hong-Wu Chen. 2016 Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy. Cell Death&Differentiation. doi: 10.1038/cdd.2016.92.
Junjian Wang, Zhijian Duan, Zoann Nugent, June X. Zou, Alexander D. Borowsky, Yanhong Zhang, Clifford G. Tepper, Jian Jian Li, Oliver Fienh, Jianzhen Xu, Leigh Murphy, Hsing-Jien Kung and Hong-Wu Chen. 2016 Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes. Cancer Letters. 378(2):69-79. doi: 10.1016/j.canlet.2016.05.004.
Jianwei Zheng, Junfeng Wang, Qian Wang, Hongye Zou, Hong Wang, Zhenhua Zhang, Jianghe Chen, Qianqian Wang, Panxia Wang, Yueshan Zhao, Jing Lu, Xaiolei Zhang, Songtao Xiang, Haibin Wang, Jinping Lei, Hong-Wu Chen, Peiqing Liu, Yonghong Liu*, Fanghai Han*, Junjian Wang*. 2020 Targeting castration-resistant prostate cancer with a novel RORγ antagonist elaiophylin, Acta Pharmaceutica Sinica B,?10(12), 2313-2322 Jul 12,2020 https://doi.org/10.1016/j.apsb.2020.07.001
Jing Lu, Jingyan Li, Yuehuai Hu, Dayue Darrel Duan, Zhen Guo, Duanping Sun, Panxia Wang, Kaiteng Guo, Si Gao, Jianmin Jiang, Junjian Wang*, Peiqing Liu*, 2019 Chrysophanol protects against doxorubicin-induced cardiotoxicity by suppressing cellular PARylation, Acta Pharmaceutica Sinica B, 9(4): 782-793.
近三年发表其他论文
?2020年
Jiao-jiao Yu, Dan-dan Zhou, Xiao-xiao Yang, Bing Cui, Fengwei Tan, Junjian Wang, Ke Li, Shuang Shang, Cheng Zhang, Xiao-xi Lv, Xiao-wei Zhang, Shan-shan Liu, Jin-mei Yu, Feng Wang, Bo Huang, Fang Hua, and Zhuowei Hu. 2020, TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target. Nature Communications. 2020 Jul 21;11(1):3660. doi: 10.1038/s41467-020-17385-0
Qianqian Wang, Jianwei Zheng, June X. Zou, Jianzhen Xu, Fanghai Han, Songtao Xiang, Peiqing Liu, Hong-Wu Chen*, Junjian Wang*. 2020, S-adenosylhomocysteine (AdoHcy)-dependent methyltransferase inhibitor DZNep overcomes breast cancer tamoxifen resistance via induction of NSD2 degradation and suppression of NSD2-driven redox homeostasis. Chem Biol Interact. 2020 Jan 27:108965. doi: 10.1016/j.cbi.2020.108965.
Wei-Hao Chen, Kun-Long Li, Xiu-Ping Lin, Sheng-Rong Liao, Bin Yang, Xue-Feng Zhou, Jun-Jian Wang*, Yong-Hong Liu*, and Jun-Feng Wang*. 2020, Antioxidant CPA-type indole alkaloids produced from the deep-sea derived fungus Aspergillus sp. SCSIO41024. Natural Product Research. 2020 Apr 7:1-5. doi: 10.1080/**.2020.**.
Menghan Gao, Lang Guo, Hong Wang, Jialuo Huang, Fanghai Han, Songtao Xiang*, Junjian Wang*. 2020, Orphan Nuclear Receptor RORγ Confers Doxorubicin Resistance in Prostate Cancer. Cell Biology International, 44(10):2170-2176. doi: 10.1002/cbin.11411.
Delong Chen，Zhen Ye，Chao Wang，Qingqing Wang，Haibin Wang，Vincent Kuek，Ziyi Wang，Heng Qiu，Jinbo Yuan，Jacob Kenny，Fan Yang，Jianbo He，Yun Liu， Gang Wang，Meng Zhang，Gangyu Zhang，Junjian Wang，Peng Chen*，Jiake Xu*. 2020 Arctiin abrogates osteoclastogenesis and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation. Pharmacological Research. 2020 May 23, 104944
Yuehuai Hu^#, Jie Liu^# , Jing Lu, Panxia Wang, Jianxing Chen, Ying Guo, Fanghai Han, Junjian Wang, Wei Li*, Peiqing Liu*. 2020, sFRP1 protects H9c2 cardiac myoblasts from doxorubicin-induced apoptosis by inhibiting the Wnt/PCP-JNK pathway. Acta Pharmacol Sin, 2020 Apr 1. doi: 10.1038/s41401-020-0364-z.
Zhijian Duan, Nicolas P. Andrews, Christopher Z. Chen, Ming Fan, Junjian Wang, Jing Shen, Jian?Jian Li, Hong?Wu Chen*, 2020, Targeting bromodomain protein ANCCA/ATAD2 enhances the efficacy of DNA?damaging chemotherapy agents and radiation. Oncol Rep. 43(1):318-327. doi: 10.3892/or.2019.7418. ? ? ? ? 2019年
Junjian Wang, June X. Zou, Hong Wang, Zhijian Duan, Haibin Wang, Peng Chen, Peiqing Liu, Jianzhen Xu, Hong-Wu Chen, 2019, Histone methyltransferase NSD2 mediates survival and invasion of triple-negative breast cancer cells via stimulating ADAM9-EGFR-AKT signaling, Acta Pharmacol Sin. 2019 40(8):1067-1075.
Xiao‐Wei Luo, Cheng‐Hai Gao, Fang‐Hai Han, Xian‐Qiang Chen, Xiu‐Ping Lin, Xue‐Feng Zhou, Jun‐Jian Wang*, Yong‐Hong Liu*. 2019, A new naphthopyranone from the sponge‐associated fungus Penicillium sp. XWS02F62. Magnetic Resonance in Chemistry. https://doi.org/10.1002/mrc.4930
Jing Yuan, Huiqi Hong, Yuhong Zhang, Jing Lu, Youhui Yu, Xueying Bi, Junjian Wang*, Jiantao Ye*, 2019, Chrysophanol attenuated isoproterenol-induced cardiac hypertrophy through inhibiting JAK2/STAT3 signaling pathway. Cell Biology International, doi: 10.1002/cbin.11146.
Demin Cai, Junjian Wang, Bei Gao, Jin Li, Feng Wu, June X. Zou, Jianzhen Xu, Yuqian Jiang, Hongye Zou, Zenghong Huang, Alexander D. Borowsky, Richard J. Bold, Primo N. Lara, Jian Jian Li, Xinbin Chen, Kit S. Lam, Ka-Fai To, Hsing-Jien Kung, Oliver Fiehn, Ruqian Zhao, Ronald M. Evans & Hong-Wu Chen. 2019 RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype. Nature Communications, OCT 11; 10(1): 4621.?
Yan Zhang, Xishan Wu, Xiaoqian Xue, Chenchang Li, Junjian Wang, Rui Wang, cheng Zhang, Chao Wang, Yudan Shi, Lingjiao Zou, Qiu Li, Zenghong Huang, Xiaojuan Hao, Kerry M. Loomes, Donghai Wu, Hongwu Chen, Jinxin Xu, and Yong Xu, 2019，Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer (CRPC). J Med Chem. 2019 Apr 9. doi: 10.1021/acs.jmedchem.9b00327.
Xiaoyan Pang, Guodi Cai, Xiuping Lin, Limbadri Salendra, Xuefeng Zhou, Bin Yang, Junjian Wang, Junfeng Wang*, Shihai Xu*, Yonghong Liu*,?2019, New Alkaloids and Polyketides from the Marine Sponge-Derived Fungus Penicillium, Marine Drugs, 17(7):pii:E398.
Panxia Wang, Luping Wang, Jing Lu1*, Yuehuai Hu, Qianqian Wang, Zhenzhen Li, Sidong Cai, Liying Liang, Kaiteng Guo, Jiyan Xie, Junjian Wang, Rui Lan, Juan Shen*, Peiqing Liu*. 2019, SESN2 protects against doxorubicin-induced cardiomyopathy via mediating mitochondrial function and mitophagy. Journal of Molecular and Cellular Cardiology. 133:125-137. doi: 10.1016/j.yjmcc.2019.06.005.?
Yuehuai Hu, Zhen Guo, Jing Lu*, Panxia Wang, Shuya Sun, Yiqiang Zhang, Jingyan Li, Qiyao Zheng, Kaiteng Guo, Junjian Wang, Jianmin Jiang*, Peiqing Liu*, 2019 sFRP1 has a biphasic effect on doxorubicin-induced cardiotoxicity in a cellular location-dependent manner in NRCMs and Rats, Archives of Toxicology, 93(2):533-546. ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 2018年
Zhang M, Zhang Y, Song M, Xue X, Wang J, Wang C, Zhang C, Li C, Xiang Q, Zou L, Wu X, Wu C, Dong B, Xue W, Zhou Y, Chen H, Wu D, Ding K, Xu Y. 2018 Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC). J Med Chem; 61(7):3037-3058. doi: 10.1021/acs.jmedchem.8b00103.
Xue X, Zhang Y, Wang C, Zhang M, Xiang Q, Wang J, Wang A, Li C, Zhang C, Zou L, Wang R, Wu S, Lu Y, Chen H, Ding K, Li G, Xu Y. 2018 Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer. Eur J Med Chem. 2018 May 25;152:542-559. doi: 10.1016/j.ejmech.2018.04.034.
Guo Z, Lu J, Li J, Wang P, Li Z, Zhong Y, Guo K, Wang J, Ye J, Liu P. 2018 JMJD3 inhibition protects against isoproterenol-induced cardiac hypertrophy by suppressing β-MHC expression. Mol Cell Endocrinol. 2018 May 10. pii: S0303-7207(18)30157-6. doi: 10.1016/j.mce.2018.05.009.
?
备注 * Corresponding author
所有发表论文
https://www.ncbi.nlm.nih.gov/sites/myncbi/1BiXnpoz7cQQIt/bibliography/**/public/?sort=date&direction=ascending
专利Title: Methods for treating cancer with RORgamma inhibitors and statins；2019.8.30，Inventors: Hongwu Chen; Demin Cai; Yuqian Jiang; Junjian Wang; June X. Zou; Hongye Zou; PCT/US2019/049178;
一种吲哚类化合物及其合成方法和应用；申请人：赵德鹏，王军舰等；申请号：.6；申请日期：2019.06.14，发文日期：2019.06.18
Title: Methods for treating cancer with RORgamma inhibitors. 2017, Inventors: Hongwu Chen, Junjian Wang, June X. Zou, Xiaoqian Xue, Tan Zhang, and Yong Xu. PCT/US2017/13966
Title: Methods for treating cancer with RORgamma inhibitors. 2016, Inventors: Hongwu Chen, Junjian Wang, June X. Zou, PCT/US2016/021983
获奖情况2016 前列腺癌基金会Challenge Award
?